Quick Answer
Sionna Therapeutics, Inc. reported Operating Income of -$88.98 million for fiscal year 2025.
Sionna Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$88.98M | -26.1% |
| 2024 | -$70.56M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$23.80M | +14.9% | -8.7% |
| June 30, 2025 | -$21.91M | -94.0% | -11.4% |
| March 31, 2025 | -$19.66M | -49.5% | +29.7% |
| September 30, 2024 | -$27.98M | — | -147.8% |
| June 30, 2024 | -$11.29M | — | +14.1% |
| March 31, 2024 | -$13.15M | — | — |
- Sionna Therapeutics, Inc. showed a decrease of -26.1% in Operating Income compared to the prior fiscal year.
- Over the 2024–2025 period, Sionna Therapeutics, Inc.’s operating income has declined by 26.1% (from -$70.56 million to -$88.98 million).
- The most recent figure is from Sionna Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 2, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: